An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response
To access this article, please choose from the options below
View this article's video abstract atwww.gastrojournal.org
Conflicts of interest These authors disclose the following: Alexander Thompson, Kevin Shianna, David Goldstein, and John McHutchison are co-inventors of a patent application based on the interleukin-28B discovery. The remaining authors disclose no conflicts.
Funding Supported by funding from the Duke Clinical Research Institute, a generous research gift from the Richard B. Boebel Family Fund, the National Health and Medical Research Council of Australia, the Gastroenterology Society of Australia, and the Royal Australasian College of Physicians (A.J.T.).
PII: S0016-5085(10)00841-3
doi:10.1053/j.gastro.2010.05.079
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

